SCT Promoter Methylation is a Highly Discriminative Biomarker for Lung and Many Other Cancers
Adwait Sathe,Yu-An Zhang,Xiaotu Ma,Pradipta Ray,Daniela Cadinu,Yi-Wei Wang,Xiao Yao,Xiaoyun Liu,Hao Tang,Yunfei Wang,Ying Huang,Changning Liu,Jin Gu,Martin Akerman,Yifan Mo,Chao Cheng,Zhenyu Xuan,Lei Chen,Guanghua Xiao,Yang Xie,Luc Girard,Hongyang Wang,Stephen Lam,Ignacio I Wistuba,Li Zhang,Adi F Gazdar,Michael Q Zhang
DOI: https://doi.org/10.1109/lls.2015.2488438
2015-01-01
IEEE Life Sciences Letters
Abstract:Aberrant DNA methylation has long been implicated in cancers. In this work we present a highly discriminative DNA methylation biomarker for non-small cell lung cancers and fourteen other cancers. Based on 69 NSCLC cell lines and 257 cancer-free lung tissues we identified a CpG island in SCT gene promoter which was verified by qMSP experiment in 15 NSCLC cell lines and 3 immortalized human respiratory epithelium cells. In addition, we found that SCT promoter was methylated in 23 cancer cell lines involving >10 cancer types profiled by ENCODE. We found that SCT promoter is hyper-methylated in primary tumors from TCGA lung cancer cohort. Additionally, we found that SCT promoter is methylated at high frequencies in fifteen malignancies and is not methylated in ~1000 non-cancerous tissues across >30 organ types. Our study indicates that SCT promoter methylation is a highly discriminative biomarker for lung and many other cancers.